// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























387 Abstracts

Type Natriuretic Peptide (BNP)

J. Su - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Troponin-T, NT-proBNP, and Serum Creatinine at Presentation Predict Outcomes in Patients with Cardiac Sarcoidosis

Nikhil Kolluri - Heart Failure Society of America (HFSA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac sarcoidosis

Angiotensin II

Association between hospital care quality and readmission among Japanese patients with heart failure. -From JROAD-DPC study-

K Nakao - European Society of Cardiology (ESC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Spironolactone

Association of plasma D-dimer and B-type natriuretic peptide levels with stroke mechanism, severity, and outcome (P2.229)

Hyun-Wook Nah - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

 Does NYHA class predict health-related quality of life?

Angela Gallagher - British Cardiovascular Society (BCS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

IMPELLA AS A BRIDGE TO EMERGENT VALVE-IN-VALVE TRANSCATHETER AORTIC VALVE REPLACEMENT IN SEVERE PROSTHETIC AORTIC VALVE STENOSIS

Ahsan Khan - American College of Cardiology (ACC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Severe Aortic Stenosis

N/A

5-FLUOROURACIL INDUCED HEART FAILURE: RECOGNIZING A RARE SIDE EFFECT IN A COMMON CHEMOTHERAPEUTIC AGENT

Maitreyee Rai - American College of Cardiology (ACC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Mitral valve regurgitation

Adrucil injection

ECHOCARDIOGRAPHIC MYOCARDIAL STRAIN IMAGING AND TROPONIN T FOR EARLY DETECTION OF CARDIOTOXICITY IN PATIENTS RECEIVING ANTHRACYCLINES

Kazuko Tajiri - American College of Cardiology (ACC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiotoxicity

N/A

IMMUNE CHECKPOINT INHIBITOR-RELATED MYOCARDITIS PRESENTING AS VENTRICULAR TACHYCARDIA STORM

Jessica Parr - American College of Cardiology (ACC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Disseminated intravascular coagulation

Mycophenolic acid

Novel Use of Perioperative Data for Early Diagnosis of Heart Failure: A Machine Learning Approach

Michael Mathis - American Society of Anesthesiologists (ASA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Cardiac arrest

N/A

B-type natriuretic peptide: a biomarker of cardiovascular risk in type 2 diabetes.

Ibtissem Oueslati - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Non-classical factors of cardiovascular risk in acromegaly

Betina Biagetti - European Congress of Endocrinology (ECE) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

ILS-969

Can the PHAROS Predict the Future? - Identifying High Risk Phenotypes Among Patients with Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)

N. R. Fox - American Thoracic Society (ATS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

A Cardiac-Specific Regulatory Genetic Variant for Protein Kinase C α is Significantly Associated with Mortality in Patients with Heart Failure

Jasmine A. Luzum - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Assessment of Soluble ST2 and BNP in Pediatric Patients with Left Ventricular Dysfunction

Hugo R. Martinez - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Development of Useful Conversion Equation between B-type Natriuretic Peptide and N-terminal pro BNP Levels

Shintaro Kasahara - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Angiotensin II

Admission pro-B-type Natriuretic Peptide by Obesity Category in Hospitalized Heart Failure with Preserved Ejection Fraction

Joban Vaishnav - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Dopamine hydrochloride

Lower High Sensitive Troponin T Level is Associated with Favorable Response to Cardiac Resynchronization Therapy in Heart Failure Patients

Jaewon Oh - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry

Kelly McHugh - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Biomarkers for the prediction of mortality in patients with infective endocarditis

R F Siciliano - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved